The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19

被引：19
|
作者：
Gozzetti, Alessandro [1 ]
Capochiani, Enrico [2 ]
Bocchia, Monica [1 ]
机构：
[1] Univ Siena, Div Hematol, Siena, Italy
[2] Azienda USL Toscana NordOvest, Ctr Translat Med, Hematol Unit, Livorno, Italy
来源：
LEUKEMIA | 2020年 / 34卷 / 10期
关键词：
D O I：
10.1038/s41375-020-01038-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2815 / 2816
页数：2
相关论文
共 50 条
  • [41] CD4+T CELL FUNCTIONS ARE POTENTLY SUPPRESSED BY THE JANUS KINASE 1/2 (JAK1/JAK2) INHIBITOR RUXOLITINIB
    Yajnanarayana, S. Parampalli
    Stuebig, T.
    Cornez, I.
    Alchalby, H.
    Wolschke, C.
    Heine, A.
    Brossart, P.
    Kroeger, N.
    Wolf, D.
    HAEMATOLOGICA, 2014, 99 : 120 - 120
  • [42] CD4+ T Cell Functions Are Potently Suppressed By The Janus Kinase 1/2 (JAK1/JAK2) Inhibitor Ruxolitinib
    Yajnanarayana, Sowmya Parampalli
    Cornez, Isabelle
    Heine, Annkristin
    Brossart, Peter
    Wolf, Dominik
    BLOOD, 2013, 122 (21)
  • [43] CD4+T CELL FUNCTIONS ARE POTENTLY SUPPRESSED BY THE JANUS KINASE 1/2 (JAK1/JAK2) INHIBITOR RUXOLITINIB
    Yajnanarayana, S. Parampalli
    Cornez, I.
    Schoenberg, K.
    Heine, A.
    Brossart, P.
    Wolf, D.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S19 - S19
  • [44] Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial
    Belperio, John
    Nguyen, Tuan
    Lombardi, David A.
    Bogus, Maxim
    Moskalenko, Valentyn
    Singh, Dave
    Haumann, Brett
    Bourdet, David L.
    Kaufman, Elad
    Pfeifer, Nathan D.
    Thompson, Corbin G.
    Woo, Jacky
    Moran, Edmund J.
    Saggar, Rajeev
    BMJ OPEN RESPIRATORY RESEARCH, 2023, 10 (01)
  • [45] Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19
    Peterson, Danielle
    Damsky, William
    King, Brett
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) : E67 - E68
  • [46] Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals
    Melikhov, Oleg
    Kruglova, Tatiana
    Lytkina, Karine
    Melkonyan, Georgy
    Prokhorovich, Elena
    Putsman, Gleb
    Rodoman, Grigory
    Vertkin, Arkady
    Zagrebneva, Alena
    Stebbing, Justin
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (09) : 1245 - 1246
  • [47] The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever
    Sahin, Mehmet
    Remy, Melissa M.
    Merkler, Doron
    Pinschewer, Daniel D.
    MICROORGANISMS, 2021, 9 (03) : 1 - 9
  • [48] Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
    Spaner, David E.
    Wang, Guizhei
    McCaw, Lindsay
    Li, Yanmei
    Disperati, Patricia
    Cussen, Mary-Ann
    Shi, Yonghong
    HAEMATOLOGICA, 2016, 101 (05)
  • [49] COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib
    Ucciferri, Claudio
    Auricchio, Antonio
    Marinari, Stefano
    Vecchiet, Jacopo
    Falasca, Katia
    EUROPEAN JOURNAL OF INFLAMMATION, 2021, 19
  • [50] Increased Risk of Keratinocyte Carcinomas, Merkel Cell Carcinoma, and Other Skin Cancers in Patients Treated With Janus Kinase 1 and 2 Inhibitor, Ruxolitinib
    Dababneh, Nadine Elias
    Maazi, Mahan
    Dababneh, Said
    Popradi, Gizelle
    Litvinov, Ivan V.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024, 28 (05) : 486 - 487
12345